Randomized placebo-controlled trial of the bradykinin B2 receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial
WR Lumry, HH Li, RJ Levy, PC Potter, H Farkas… - Annals of Allergy …, 2011 - Elsevier
BACKGROUND: The For Angioedema Subcutaneous Treatment (FAST)-3 study was a
phase III, randomized, double-blind, placebo-controlled study of icatibant (bradykinin B2
receptor antagonist) in subjects with hereditary angioedema (HAE) resulting from C1-INH
deficiency or dysfunction (type I/II). OBJECTIVE: To investigate icatibant efficacy and safety
in subjects with acute HAE attacks. METHODS: Subjects with moderate to very severe
cutaneous or abdominal symptoms received icatibant (n= 43) or placebo (n= 45). Five …
phase III, randomized, double-blind, placebo-controlled study of icatibant (bradykinin B2
receptor antagonist) in subjects with hereditary angioedema (HAE) resulting from C1-INH
deficiency or dysfunction (type I/II). OBJECTIVE: To investigate icatibant efficacy and safety
in subjects with acute HAE attacks. METHODS: Subjects with moderate to very severe
cutaneous or abdominal symptoms received icatibant (n= 43) or placebo (n= 45). Five …